trial

Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia

NCTId NCT01363349
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Terminated
Enrollment 269 (actual)
Sponsored by BioLineRx, Ltd.
Primary completion 2013-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Terminated
Enrollment
269 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2011-05
Primary completion
2013-03
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
CYP-1020Risperidone

Sponsors

BioLineRx, Ltd.Lead Sponsor

Investigators

1
Arnon Aharon, MDStudy Chair

Sites

39 total
Ahmedabad, IndiaAurangabad, IndiaBangalore, IndiaChennai, IndiaHyderabad, IndiaHyderabad, IndiaJaipur, IndiaKanpur, IndiaKolkata, IndiaLudhiana, IndiaMangalore, IndiaMumbai, India

Linked catalysts

1
Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia — primary completion2013-03

Facts & assertions

4 sourced
Enrollment
269
Phase
PHASE2,PHASE3
Primary Completion Date
2013-03
Status
TERMINATED
relationships
The graph out of here
drug
CYP-1020
drug
Risperidone
drug
lead_sponsor
BioLineRx, Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication
Cognitive Effect on Schizophrenic Patients
indication
investigator
Arnon Aharon, MD
person